-

Newomics Announces a Global Network of Distributors

BERKELEY, Calif.--(BUSINESS WIRE)--Newomics Inc., a commercial-stage biotechnology company that sells and develops mass spectrometry products and services, today announced it has completed the final link in creating a World-Wide Distribution and Support Network. The Newomics distribution network covers Europe (MS Wil B.V.), Japan (AMR, Inc.), Taiwan (Wise Analysis Instruments), and China (Neoline Technology Co.), besides North America by our own expanding salesforce and with active co-marketing agreements with leading mass spectrometry vendors.

“We continue to extend our reach to support the demand around the globe, fueled by the sales momentum that the company has experienced in the last year, since the initial release of our M3 emitter in June 2019,” said Dr. Daojing Wang, Founder and CEO, Newomics.

The Newomics award-winning silicon multinozzle emitter technology enables optimization of sensitivity, throughput, and robustness for LC/MS by splitting the LC eluent evenly into multiple flows at the emitter, thereby dramatically enhancing the ionization efficiency. The first commercially available multinozzle emitter (Newomics® M3 emitter) has been optimized for microflow LC-nanospray MS. The applications of M3 emitters have been successfully demonstrated in proteomics, lipidomics, and native MS analysis. The company has a robust product roadmap including additional lines of emitters, as well as the new MnESI (Microflow nanospray ESI) ion source scheduled for shipments in Q4, 2020.

“We are excited about the acceptance of the Newomics products globally, which has drawn top-tier distributors world-wide to actively represent and support us in these markets,” Daojing continued.

About Newomics

Newomics Inc. is dedicated to creating and commercializing innovative (New) and integrative (Omics) platforms and solutions for precision medicine. The company’s first product, the M3 multinozzle emitter for LC-MS, enables the robustness of microflow LC and the sensitivity of nanospray ionization MS. The plug-and-play M3 emitters are currently interfaced to diverse MS instruments and can be ordered at www.newomics.com.

Contacts

Na Parra, Ph.D.
Senior Director of Marketing
Newomics
408-806-8236
nparra@newomics.com

Newomics Inc.

Details
Headquarters: Berkeley, CA
CEO: Daojing Wang
Employees: 10
Organization: PRI

Release Versions

Contacts

Na Parra, Ph.D.
Senior Director of Marketing
Newomics
408-806-8236
nparra@newomics.com

More News From Newomics Inc.

Newomics Inc. Places Its 100th Mass Spectrometry Front-end System

BERKELEY, Calif.--(BUSINESS WIRE)--Berkeley-based precision medicine solutions provider Newomics Inc. has announced the commercial placement of its 100th mass spectrometry front-end system, which has contributed to successful customer applications in the development of biotherapeutics such as Covid-19 antibodies and gene therapy, blood-based clinical diagnosis, and proteomics research. The system is made up of an ion source integrated with breakthrough silicon microfluidic chips including M3 em...

CORRECTING and REPLACING Newomics Announces Collaborations on High-throughput Bioanalysis

BERKELEY, Calif.--(BUSINESS WIRE)--Please replace the release dated March 2, 2022 with the following corrected version due to multiple revisions. The updated release reads: NEWOMICS ANNOUNCES COLLABORATIONS ON HIGH-THROUGHPUT BIOANALYSIS Newomics Inc., a biotechnology company commercializing mass spectrometry solutions for molecular detection, today announced collaborations with Bruker Corporation, a company with differentiated high-value life science research and diagnostics solutions, on a no...

Newomics Announces Sales Team and New Kits

BERKELEY, Calif.--(BUSINESS WIRE)--Newomics Inc., a biotechnology company developing and commercializing mass spectrometry solutions, today announced that it has established a North America Sales Team, and it is launching a new product to enhance the existing mass spectrometry workflows. Newomics continues its dedication to creating and commercializing innovative (New) and integrative (Omics) platforms and solutions for precision medicine. The MnESI platform (M3 multinozzle emitter + MnESI sour...
Back to Newsroom